Dimiter Dimitrov | Professor Of Medicine
University of Pittsburgh

Dimiter Dimitrov, Professor Of Medicine, University of Pittsburgh

Dr. Dimitrov graduated and completed his PhD at the University of Sofia, Sofia, Bulgaria, and thereafter he worked in the Bulgarian Academy of Sciences where he defended his ScD and was Professor of Biophysics until he joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990. There he was tenured as Senior Investigator and appointed at the Senior Biomedical Research Service. He joined the University of Pittsburgh in 2017 as the Director of the new Center for Antibody Therapeutics (CAT) where he is Professor of Medicine with tenure. He is expert in display/screening/libraries methodologies, antibody engineering, and protein biochemistry as well as in mathematical modeling, immunology, virology, physical chemistry and biophysics. His major long-term goal is the development of clinically useful therapeutics and vaccines against cancer, viruses and aging based on human monoclonal including engineered antibody domains, chimeric antigen receptors, antibody drug conjugates, full size antibodies, bispecific antibodies and antibody-based fusion proteins. Two of the antibodies (to CD22 and mesothelin) he and his group identified and characterized, and his collaborators further developed, are in clinical trials for therapy of cancer, and one (to the envelope glycoproteins of Hendra and Nipah viruses) was approved for clinical use on compassionate basis for therapy of the disease caused by these viruses. He has authored or coauthored more than 400 articles cited more than 28,000 times, several books and is inventor or coinventor of more than 100 inventions, patent applications or patents.


Festival of Biologics Day 1 @ 17:50

Human monoclonal antibodies as therapeutics against SARS-COV-2 and related viruses

  • Rapid identification of human antibodies by phage display
  • High affinity/avidity to SARS-CoV-2 S glycoprotein and mutants found in patients (Li W et al PNAS, Cell; Sun Z et al mAbs, 2020; Zhu X et al PLOS Biology, Sun Z et al bioRxiv, 2021) as well as to bat coronavirus S receptor binding domains.
  • Potent and specific neutralization of SARS-CoV-2 in hACE2 expressing transgenic mice and hamsters as well as mouse ACE2 adapted SARS-CoV-2 in wild type BALB/c mice at doses as low as 2 mg/kg.
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers